ARWR

41.3705.22%
WD

William D. Waddill

Independent Director

Mr. William D. Waddill, also known as Will, was an Independent Director of Turnstone Biologics Corp. from April 15, 2024 until August 11, 2025. Mr. Waddill has been Independent Director of Annexon, Inc. since August 12, 2021 and also serves as Interim Lead Independent Director since June 2026, Arrowhead Pharmaceuticals, Inc. since January 2018 and Protagonist Therapeutics, Inc. since July 01, 2016. He serves as Independent Lead Director of Arrowhead Pharmaceuticals, Inc. Mr. Waddill served as the Chief Financial Officer, Senior Vice President, Treasurer and Secretary of Calithera Biosciences, Inc. from April 1, 2014 to December 31, 2016. Mr. Waddill served as the Chief Financial Officer and Senior Vice President of OncoMed Pharmaceuticals, Inc. from October 2007 to March 31, 2014 and as its Treasurer and Assistant Secretary from October 2007 to March 31, 2014. He began his career in commercial banking and public accounting and has been in the biotechnology industry for over many years. He also served as Principal Accounting Officer of OncoMed Pharmaceuticals, Inc. until March 31, 2014. Mr. Waddill served as Chief Financial Officer of EnVivo Pharmaceuticals, Inc., (alternate name FORUM Pharmaceuticals Inc.). He served as an Acting Chief Financial Officer and Advisor of Amyris, Inc. For many years, he was consulting in the Life Science start-up arena in Boston and San Francisco. He served as the Chief Financial Officer and Senior Vice President of Ilypsa, Inc. from October 2006 to September 2007, where he was responsible for all corporate financial matters. He joined Amyris Inc., from Square One Finance, a Life Science financial consulting business. He founded Square One Finance in 1993 and served as its Principal from February 2000 to September 2006. He served as President of Square One Finance. Mr. Waddill has developed a unique understanding of the start-up environment. He was involved with the founding and financing of several companies including Renovis, Genospectra and Inspire Pharmaceuticals. He served as Senior Director of Finance and Administration at Exelixis, Inc. He served as Senior Director of Finance and Chief Financial Officer of Medical Science Partners for few years. He served as Head of finance at the Boston venture capital firm Medical Science Partners (MSP). Mr. Waddill managed the finances of emerging-life science companies as part-time Chief Financial Officer. As a consultant, he managed three initial public offerings (Exelixis, Inc.; Damon, Inc.; ISI Systems, Inc.) and four mergers (Creagen, Inc; Genesis, Inc.; Cardio Canada, Inc.; Metaxen, Inc.). He has many years of life science experience directing fundraising, financial operations and strategic analysis at numerous venture-backed and publicly-held life science companies. He has been a Director of Sorbent Therapeutics, Inc., since June 18, 2014. He serves as a Member of the Advisory Board at The DiBari Group, LLC. He serves on the board of the Association of Bioscience Financial Officers. He served as the Chairman of the Biotechnology Industry Organization (BIO) BIO Business Solutions Advisory Board. He has certification as a Public Accountant after work at PricewaterhouseCoopers and Deloitte and Touche. Mr. Waddill holds a BS in Accounting from University of Illinois.

Positions